L-Carnosine Pharmaceutical Grade Specifications and Sourcing Considerations for API Developers
- 1-Pentene Organic Synthesis: Reactions & Applications - April 21, 2026
- Selenious Acid Handling & Storage Guide - April 21, 2026
- Thallium Sulfate Regulations: Compliance Guide for Chemical Procurement - April 21, 2026
Introduction
L-Carnosine is a naturally occurring dipeptide that has quietly moved from academic biochemistry into active pharmaceutical development pipelines. Produced endogenously in skeletal muscle and brain tissue, it is now studied seriously across ophthalmic preparations, neuroprotective therapeutics, and anti-ageing formulations, and for good reason. The science behind it is solid.
That said, working with L-carnosine as an API introduces a specific set of material requirements that many developers underestimate early in their programs. Sourcing is rarely the bottleneck. Getting the right purity, the right documentation, and a supplier whose manufacturing standards hold up under regulatory scrutiny is where projects slow down.
This article covers theL-carnosine API specifications that matter most, what a complete certificate of analysis should contain, and what pharmaceutical manufacturers and research teams should weigh before committing to a bulk supplier.
Chemical Overview and Key Properties
Structurally, L-carnosine is a dipeptide formed by beta-alanine and L-histidine connected through an amide bond. It presents as a white to off-white crystalline powder and is freely soluble in water, making it compatible with a range of liquid dosage form strategies.
Key physicochemical data:
| Property | Value |
| CAS Number | 305-84-0 |
| Molecular Formula | C₉H₁₄N₄O₃ |
| Molecular Weight | 226.23 g/mol |
| Optical Rotation | +20° to +22° (c=1, H₂O) |
| Solubility | Freely soluble in water |
| pH (1% solution) | 7.0 – 8.5 |
| Melting Point | 260 – 263°C (decomposition) |
One property that developers cannot afford to overlook is its susceptibility to enzymatic hydrolysis by carnosinase (CN1 and CN2), particularly in plasma. This has real formulation implications for systemic delivery routes and must be addressed during early development planning.
Pharmaceutical and Industrial Applications
L-Carnosine is not a single-use compound. Across different formulation contexts, it serves meaningfully different roles.
Ophthalmic Formulations: The prodrug form, N-acetylcarnosine, is already commercially available in eye drops targeting lens protein glycation linked to cataract development. L-carnosine itself is studied in direct ophthalmic preparations, where its antioxidant buffering behavior is relevant to ocular oxidative stress.
Neuroprotective Research: In neural tissue, L-carnosine functions as a histidine-containing dipeptide with demonstrated antioxidant properties. Research programs investigating oxidative stress pathways in Alzheimer’s disease and autism-spectrum disorder have incorporated it as an adjunct compound in formulation studies.
Wound Healing and Dermatology: Topical applications, both pharmaceutical and cosmeceutical, leverage L-carnosine’s role in fibroblast activation and collagen synthesis. It is not a trivial additive in these formulations; its functional contribution to tissue repair is reasonably well characterised.
Anti-Glycation Therapeutics: L-Carnosine’s ability to inhibit the formation of advanced glycation end-products (AGEs) has positioned it as a candidate ingredient in metabolic disease pipelines, particularly for formulations targeting diabetic complications.
Mechanism of Action and Formulation Relevance
Knowing the biochemistry of L-carnosine is not just academic for a formulator; it directly informs compatibility decisions and stability strategy.
L-Carnosine functions as a physiological pH buffer (pKa ~6.83), a free-radical scavenger, and a chelator of divalent metal ions, including copper (Cu²⁺), often introduced through compounds such as Copper(II) chloride, and zinc (Zn²⁺), which may be present in formulation ingredients like Zinc ricinoleate. which may be present in formulation ingredients like Zinc ricinoleate.. The imidazole ring on the histidine residue drives much of its proton-buffering capacity, while the beta-alanine component contributes to structural stability in the dipeptide.
In practical formulation terms, the metal-chelating activity can interfere with excipients that contain transition metals. This needs to be factored into compatibility screening. The stability window is equally important: L-carnosine holds up well between pH 6.5 and 8.0, but hydrolysis rates climb noticeably above pH 9 or below pH 5. Specifically for injectable and parenteral preparations, this stability profile must be incorporated into accelerated degradation studies per ICH Q1A(R2) requirements.
L-Carnosine API Specifications: What Developers Must Verify
Before approving any L-carnosine bulk supplier, pharmaceutical developers need to confirm that the material meets a defined set of quality parameters. These are not optional checkboxes; they are the foundation of a defensible development program.
Purity is the starting point. Pharmaceutical-grade L-carnosine should test at ≥98.5% by HPLC on a dried basis. For injectable or high-sensitivity applications, that threshold moves to ≥99.0%. Alongside purity, the optical rotation must fall between +20° and +22°, confirming that the L-configuration is intact. If that value is off, the batch has undergone racemization and is not suitable for use.
Heavy metals must be tested by ICP-MS, with total metals not exceeding 10 ppm. Lead and arsenic each carry individual limits of ≤1 ppm under ICH Q3D. Residual solvents, commonly DMF, methanol, or ethyl acetate, depending on the synthesis pathway, must conform to ICH Q3C Class 2 or Class 3 limits as applicable.
On the microbiological side, total aerobic count should be ≤1000 CFU/g, yeast and mold ≤100 CFU/g, with confirmed absence of E. coli and Salmonella per USP <61> and <62>. Water content, tested by Karl Fischer, should not exceed 1.0% for standard pharmaceutical-grade powder.
Finally, the impurity profile needs to account for free beta-alanine and L-histidine as the two primary hydrolytic breakdown products. Any individual unspecified impurity should be ≤0.10%, and total impurities should remain within 1.0%. A supplier that cannot provide this level of impurity characterization is not ready to supply pharmaceutical APIs.
Certificate of Analysis: What to Actually Look For
A lot-specific certificate of analysis is one of the clearest indicators of a supplier’s analytical rigour. Generic CoAs that recite specification limits without actual test results are a red flag, not a convenience.
A credible L-carnosine certificate of analysis should include the lot-specific numerical results for assay, optical rotation, loss on drying, pH, residual solvents, heavy metals, and microbial counts, each accompanied by the test method reference and a QC-approved signature with the testing date.
If a supplier cannot produce documentation to this standard, they should not be considered for pharmaceutical API supply. This is not a high bar; it is the minimum expected of any GMP-compliant operation.
Regulatory and Safety Considerations
L-Carnosine holds GRAS status for dietary use in the United States and appears in European Pharmacopoeia supplement monographs. For pharmaceutical API applications, however, GRAS status alone carries no regulatory weight. ICH compliance across impurity characterisation (Q3A/B), residual solvents (Q3C), and elemental impurities (Q3D) must be addressed through documented supplier qualification.
GMP certification from a recognised authority, such as the FDA, EMA, or WHO, is a baseline requirement for clinical or commercial pharmaceutical sourcing. Where available, developers should request site master files or drug master files (DMFs) and conduct a structured technical audit before approving a new supplier.
How Sarchem Laboratories USA Supports API Developers
Sarchem Laboratories Inc. USA supplies pharmaceutical-grade L-carnosine and specialty amino acid derivatives to API developers, contract manufacturers, and research institutions that need traceable, fully documented materials not just compliant on paper, but auditable in practice.
Custom Synthesis and Purity Grades: Sarchem manufactures L-carnosine to client-defined specifications, including high-purity grades of ≥99.5% by HPLC for clinical and research-grade applications. Custom particle-size distributions and moisture-content targets can be built into production to meet formulation-specific requirements.
Full Analytical Documentation: Every lot ships with a comprehensive certificate of analysis covering HPLC assay, optical rotation, Karl Fischer moisture, residual solvents, ICP-MS heavy metals, and microbial testing. Method validation summaries are available on request.
Regulatory Support: Manufacturing documentation at Sarchem is aligned with ICH Q7 GMP guidelines for APIs. Technical dossiers, stability data packages, and impurity qualification reports can be prepared to support regulatory submissions and drug master file filings.
Scalable Bulk Supply: Development timelines change. Whether a team needs gram quantities for early-phase screening or kilogram-scale batches for pilot production, Sarchem provides consistent, specification-matched material across supply scales.
For teams actively evaluating L-carnosine bulk suppliers, Sarchem Laboratories USA offers the analytical depth and documentation standards required by pharmaceutical development programs, without the qualification uncertainty associated with less specialized sources.
Conclusion
L-Carnosine has earned its place in pharmaceutical development through a combination of well-characterised biochemistry, versatile application potential, and a safety profile that supports broad therapeutic investigation. But the compound’s credibility in a formulation only holds if the underlying material meets the right standard.
For API developers, that means establishing clear L-carnosine purity specifications before supplier selection, requiring lot-specific certificates of analysis as a condition of purchase, and qualifying suppliers against GMP criteria relevant to the intended use. Material quality issues discovered mid-development are expensive and avoidable. Getting this right at the sourcing stage is not a detail; it is part of the development strategy.
Sarchem Laboratories USA is equipped to support that process with analytically traceable material, complete regulatory documentation, and the technical depth that serious pharmaceutical programs demand.
Frequently Asked Questions
What purity level is required for pharmaceutical-grade L-carnosine?
Pharmaceutical-grade L-carnosine typically requires ≥98.5% purity by HPLC on a dried basis, with injectable applications commonly requiring ≥99.0%.
What should a complete L-carnosine certificate of analysis include?
A valid CoA must contain lot-specific results for assay, optical rotation, residual solvents, heavy metals, water content, microbial limits, and QC-approved method references.
How do I evaluate L-carnosine bulk suppliers for API development?
Confirm GMP certification, request lot-specific CoAs, review impurity profiles, and assess whether the supplier can provide regulatory dossiers or DMF support.
Is L-carnosine stable in aqueous pharmaceutical formulations?
L-Carnosine is most stable between pH 6.5 and 8.0. Outside this range, hydrolysis into beta-alanine and L-histidine accelerates significantly.
Can L-carnosine be used in injectable pharmaceutical formulations?
Yes, but injectable-grade material requires ≥99.0% purity, strict endotoxin testing, and compatibility with sterile filtration. Formulation stability across the required pH range must also be confirmed.